MSH2 and malignant colon neoplasm: Among all the 32 families with mutations, those with hMSH2 mutation had a higher ratio of synchronous and metachronous colon cancers than families with hMLH1 mutation (33 vs. 6 %, P = 0.04) (Table 3).